Science and Research

Redefining Treatment Paradigms in First-line Advanced Non-Small-Cell Lung Cancer

Metastatic non-small-cell lung cancer is still a devastating disease; however, treatment options have diversified dramatically in the past two decades. From unselected platinum-based chemotherapy for all patients, several different treatment groups have evolved, that is, those with "druggable" targets, those with a promising immune signature, and those without any predicting factors outlined in this article. Challenge includes the intersections between these groups and the optimal treatment path. These issues will be addressed in this review.

  • Heigener, D. F.
  • Kerr, K. M.
  • Laing, G. M.
  • Mok, T. S. K.
  • Moiseyenko, F. V.
  • Reck, M.
Publication details
DOI: 10.1158/1078-0432.CCR-18-1894
Journal: Clin Cancer Res
Pages: 4881-4887 
Number: 16
Work Type: Review
Location: ARCN
Disease Area: LC
Partner / Member: CAU, Ghd, UzL
Access-Number: 30910855
See publication on PubMed

DZL Engagements

chevron-down